Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 31Terminated 21Recruiting 13Active not recruiting 7Withdrawn 4Unknown 4

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 24Lymphoid 19Myeloid 8Gastrointestinal 7Plasma cell 5Dermatologic 4Gynecologic 3Genitourinary 3Breast 3Thoracic 2Sarcoma 2Head & Neck 2Other solid neoplasm 1Classical hematology 1CNS 1

Conditions

Melanoma 3Uterine Cervical Neoplasms 1Sezary Syndrome 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 18Ipilimumab 16pembrolizumab 15Cyclophosphamide 13trametinib 9Radiotherapy 8dabrafenib 6Interleukin-2 6sargramostim 5fludarabine phosphate 5aldesleukin 5Vemurafenib 5Peripheral Blood Stem Cell Transplantation 5Fluorouracil 5130-nm albumin-bound paclitaxel 5fludarabine 4Radiosurgery 4Melphalan 4Celecoxib 4encorafenib 3durvalumab 3binimetinib 3avelumab 3Vorinostat 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Leucovorin 3Granulocyte-Macrophage Colony-Stimulating Factor 3Cytarabine 3Capecitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × fludarabine × Dermatologic × Clear all
NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

City of Hope Medical Center

Phase 1 Withdrawn
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06190249 2025-06-05

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Case Comprehensive Cancer Center

Phase 1 Withdrawn
Dermatologic

Melanoma

NCT02548468 2025-05-02

Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma

Thomas Jefferson University

Phase 1 Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02489266 2017-07-27

In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡